Last updated: September 7, 2026
PF-06651600, now marketed as ritlecitinib and branded Litfulo, is an oral, selective Janus kinase 3 (JAK3) and TEC-family kinase inhibitor developed by Pfizer. The FDA approved Litfulo on June 23, 2023, for severe alopecia areata in adults and adolescents aged 12 years and older. The commercial opportunity is concentrated in alopecia areata, with expansion potential in vitiligo, inflammatory skin disease and other immune-mediated conditions. A base-case global peak-sales range is approximately $1.3 billion to $1.8 billion, subject to payer access, treatment persistence, competition from baricitinib and emerging oral JAK inhibitors.
What is PF-06651600 and how does ritlecitinib work?
PF-06651600 is a covalent, selective inhibitor of JAK3 and the TEC kinase family. Ritlecitinib inhibits signaling pathways involved in lymphocyte activation and cytokine signaling, including pathways associated with interleukin-2, interleukin-4, interleukin-7, interleukin-15 and interleukin-21.
Unlike broad JAK inhibitors, ritlecitinib was designed to avoid direct inhibition of JAK1, JAK2 and TYK2. The product carries class-related warnings for serious infections, malignancy, major cardiovascular events and thrombosis. The FDA prescribing information recommends baseline screening for tuberculosis, viral hepatitis and selected laboratory abnormalities before treatment. [1]
Ritlecitinib is supplied as oral capsules in 50 mg and 30 mg strengths. The approved severe alopecia areata regimen is 50 mg once daily, with a loading regimen of 50 mg twice daily for four weeks in adults and adolescents aged 12 years or older. [1]
What is the current FDA regulatory status of Litfulo?
The FDA approved Litfulo under the New Drug Application pathway for severe alopecia areata in patients aged 12 years and older. The approval covered patients with substantial scalp hair loss and was based primarily on the phase 2b/3 BRAVE-AA1 and BRAVE-AA2 trials.
| Regulatory milestone |
Date |
Significance |
| First-in-human and early clinical development |
2010s |
Established JAK3/TEC pharmacology |
| Phase 2b alopecia areata studies |
2017-2021 |
Demonstrated dose-related hair regrowth |
| BRAVE-AA1 and BRAVE-AA2 phase 2b/3 program |
2018-2022 |
Supported global registration |
| FDA approval of Litfulo |
June 23, 2023 |
First US approval for ritlecitinib |
| European authorization |
2023 |
Approved for severe alopecia areata in eligible adolescents and adults |
| Commercial launch |
2023 onward |
Initial focus on US and major European markets |
The US label covers severe alopecia areata, including alopecia totalis and alopecia universalis. The treatment is not approved for androgenetic alopecia, mild patchy alopecia areata or general hair loss.
How effective is ritlecitinib in severe alopecia areata?
The pivotal endpoint was a Severity of Alopecia Tool score of 20 or less, commonly referred to as SALT20. This represents at least 80% scalp hair coverage.
In BRAVE-AA1, the proportion of patients achieving SALT20 at week 24 was materially higher with ritlecitinib 50 mg once daily than with placebo. The FDA label reported approximately 23% of patients achieving SALT20 with the approved 50 mg dose, compared with approximately 1.6% with placebo. Results in BRAVE-AA2 were directionally consistent. [1,2]
Important commercial variables remain:
- Hair regrowth develops gradually, generally over months rather than weeks.
- Many patients require chronic treatment to maintain response.
- Response rates are lower in some patients with long-standing or extensive disease.
- The treatment population includes adolescents, expanding the addressable market beyond adult-only therapies.
- Safety monitoring and the boxed warning language for JAK inhibitors can affect physician prescribing.
Ritlecitinib’s clinical differentiation is strongest in age eligibility and mechanism. Its principal commercial weakness is the need for chronic therapy and competition from another approved oral JAK inhibitor.
How does ritlecitinib compare with baricitinib?
Baricitinib, marketed in the United States as Olumiant by Eli Lilly and Incyte, was the first FDA-approved systemic treatment for severe alopecia areata. Ritlecitinib entered the market with approval for patients aged 12 years and older, while the initial US baricitinib approval was for adults.
| Attribute |
Ritlecitinib |
Baricitinib |
| Brand |
Litfulo |
Olumiant |
| Developer |
Pfizer |
Eli Lilly and Incyte |
| Mechanism |
Selective JAK3 and TEC-family inhibitor |
JAK1/JAK2 inhibitor |
| US alopecia areata approval |
Adults and adolescents 12+ |
Adults initially; pediatric expansion may affect competition |
| Dosing |
Once daily after loading regimen |
Once daily |
| Key commercial advantage |
Adolescent label and differentiated selectivity |
Earlier launch and established JAK commercial infrastructure |
| Key risk |
Safety warnings, payer restrictions, slow uptake |
Broad JAK safety concerns and future generic exposure |
| Competitive position |
Second major oral systemic entrant |
Established category leader |
The competitive outcome will depend less on nominal efficacy differences than on formulary placement, prior authorization requirements, patient persistence, physician familiarity and adolescent access.
What clinical development programs involve PF-06651600?
Alopecia areata is the validated commercial indication. Pfizer and academic investigators have also evaluated ritlecitinib in other immune-mediated disorders.
Alopecia areata
The BRAVE-AA program established efficacy in adults and adolescents with severe disease. Long-term extension studies are evaluating durability, safety and continued treatment response. Those data are relevant to reimbursement because payers may require evidence that hair regrowth persists with chronic dosing.
Vitiligo
Ritlecitinib has been evaluated in vitiligo, including programs examining facial and total-body repigmentation. Development in vitiligo is commercially attractive because the disease has a large untreated population and limited systemic treatment options. The program has not produced an FDA-approved vitiligo indication as of June 2024.
Other inflammatory diseases
Earlier studies examined ritlecitinib in rheumatoid arthritis, Crohn’s disease, ulcerative colitis and other inflammatory conditions. These programs did not create a broad approved-label platform. The strongest validated opportunity remains dermatology, where the risk-benefit profile and unmet need are more favorable.
When does ritlecitinib lose exclusivity?
The principal US regulatory protection is the orphan-drug exclusivity period for severe alopecia areata. The FDA’s approval carries seven years of orphan exclusivity, which generally runs through June 2030 for the approved indication. New chemical entity exclusivity provides five years from approval, but the orphan period is the more commercially relevant near-term protection. [1,3]
Patent protection may extend beyond regulatory exclusivity. Ritlecitinib’s composition-of-matter and related patent families are expected to create protection into the mid-2030s, subject to patent-term adjustment, patent-term extension, claim scope and successful validity challenges. The exact date for generic entry will depend on the Orange Book-listed patents and the outcome of any Paragraph IV litigation.
The practical entry timeline is therefore:
| Period |
Likely exclusivity position |
| 2023-2028 |
New chemical entity protection and patent protection |
| 2028-2030 |
Patent protection remains; orphan exclusivity continues for the approved indication |
| Around 2030 |
Orphan exclusivity expiration may permit competing approval for the same indication, subject to patents |
| Early-to-mid 2030s |
Patent estate becomes the primary barrier |
| After patent expiry |
Generic ritlecitinib entry becomes commercially feasible |
What is the Orange Book status and Paragraph IV risk?
Litfulo is an approved small-molecule drug and is eligible for Orange Book patent listing. The principal risk is ANDA certification against listed patents, followed by Paragraph IV litigation or a negotiated launch date.
No major publicly reported US Paragraph IV litigation involving Litfulo had materially changed the commercial launch outlook through June 2024. This does not eliminate future challenge risk. The most likely timing for meaningful ANDA activity is closer to the end of the five-year new chemical entity period, when generic manufacturers can file ANDAs with Paragraph IV certifications against relevant patents.
A generic entrant would face several barriers:
- Establishing pharmaceutical equivalence and bioequivalence for an oral capsule.
- Addressing the listed composition, formulation and manufacturing patents.
- Avoiding method-of-use claims covering severe alopecia areata.
- Managing REMS-like safety concerns, monitoring requirements and payer substitution rules.
- Building physician and pharmacy access in a specialty dermatology market.
Because ritlecitinib is a small molecule rather than a biologic, biosimilar competition is not the relevant risk. The relevant threat is conventional generic substitution.
What formulations and manufacturing rights protect PF-06651600?
The commercial product uses oral capsules containing ritlecitinib. Patent protection may cover several layers:
- The active ritlecitinib chemical entity.
- Salt, polymorph or crystalline forms.
- Pharmaceutical compositions and capsule formulations.
- Dosage regimens for severe alopecia areata.
- Manufacturing processes and intermediates.
- Treatment methods covering specific patient populations.
Composition-of-matter patents normally provide the strongest protection. Formulation and process patents can extend the estate, but their value depends on whether a generic can design around the claims. Method-of-use patents are particularly relevant in alopecia areata because the commercial indication is narrow and clinically defined.
The patent estate is best characterized as moderate to strong through the early 2030s, with the composition patent determining most of the value. Patent strength is lower if protection depends heavily on narrow dosing or treatment claims rather than broad chemical claims.
Which companies are challenging ritlecitinib?
The principal commercial challenger is Eli Lilly and Incyte with baricitinib. Other competitors include:
- Concert Pharmaceuticals and Sun Pharma, with deuruxolitinib, an oral JAK inhibitor under development for alopecia areata.
- Bristol Myers Squibb, AbbVie and other companies developing oral or topical immune-modulating therapies.
- Incyte, for topical and systemic dermatology programs.
- Generic manufacturers, whose entry risk increases as the 2030 regulatory-exclusivity window approaches.
The market may also face competition from non-JAK therapies, including biologics, topical agents and regenerative or procedural treatments. These products do not need to be direct substitutes to affect payer access and treatment sequencing.
What is the ritlecitinib market projection?
The US is likely to account for the largest share of ritlecitinib revenue because of high specialty-drug pricing, a sizable diagnosed population and Pfizer’s commercial infrastructure. Europe and Japan provide additional growth, but reimbursement restrictions and price controls will reduce net sales per patient.
A scenario-based projection is more useful than a single-point forecast because public company guidance did not establish a definitive long-term sales target for Litfulo as of June 2024.
| Year |
Base-case global net sales |
Primary driver |
| 2023 |
$50 million-$100 million |
Partial-year launch |
| 2024 |
$200 million-$350 million |
US uptake and European launches |
| 2025 |
$400 million-$650 million |
Payer coverage and treatment persistence |
| 2026 |
$650 million-$950 million |
Broader physician adoption |
| 2027 |
$850 million-$1.2 billion |
International expansion |
| 2028-2030 |
$1.1 billion-$1.6 billion |
Mature severe-disease penetration |
| Peak case |
$1.3 billion-$1.8 billion |
Sustained chronic use before generic pressure |
The upside case approaches $2 billion if Pfizer secures broad adolescent and adult reimbursement, demonstrates durable hair regrowth and expands into vitiligo. The downside case is below $800 million in peak sales if baricitinib retains preferred formulary status, payer restrictions remain severe, discontinuation rates are high or safety concerns suppress chronic use.
A rough patient-based model supports the base case. If the global treated population reaches 150,000 to 220,000 patients and average annual net revenue is $6,000 to $8,000 after discounts and geographic price erosion, annual sales would range from $900 million to $1.8 billion. The addressable severe alopecia areata population is larger, but only a portion is diagnosed, eligible, willing to use chronic systemic therapy and reimbursed.
What revenue exposure does Pfizer have to ritlecitinib?
Litfulo is strategically important but not material to Pfizer’s total revenue at its initial launch scale. Pfizer’s larger products and franchises, including oncology, vaccines, rare disease and inflammation, dominate corporate financial exposure.
Ritlecitinib has a favorable commercial profile because:
- It is an oral specialty product.
- The indication has high visibility among dermatologists and patients.
- Treatment is potentially chronic.
- The adolescent label broadens eligibility.
- Manufacturing complexity is lower than for biologics.
Revenue risk is concentrated in market access and persistence rather than production capacity. Pfizer’s principal execution challenge is converting clinical interest into long-term treated patients while managing JAK-class safety restrictions.
What patent litigation and settlement risks affect generic entry?
The most likely litigation path is:
- A generic manufacturer files an ANDA after the relevant filing window.
- The applicant certifies Paragraph IV against one or more Orange Book patents.
- Pfizer files an infringement action within 45 days.
- FDA approval is stayed for up to 30 months, subject to statutory conditions.
- The parties either litigate validity and infringement or negotiate a launch date.
A settlement could allow an authorized generic, an agreed future launch date or other commercial terms. No material public settlement affecting Litfulo launch timing was identified through June 2024. Patent litigation risk should increase as the market approaches the end of orphan exclusivity.
Key Takeaways
- PF-06651600 is ritlecitinib, marketed by Pfizer as Litfulo.
- The FDA approved it in June 2023 for severe alopecia areata in adults and adolescents aged 12 years and older.
- Ritlecitinib is a selective JAK3 and TEC-family inhibitor.
- Its main approved competitor is baricitinib, with additional oral JAK competition developing.
- Orphan exclusivity is expected to protect the approved indication through approximately June 2030.
- Patent protection may extend into the mid-2030s, depending on claim validity and patent-term adjustments.
- Generic, not biosimilar, competition is the relevant post-exclusivity risk.
- Base-case global peak sales are approximately $1.3 billion to $1.8 billion.
- The largest commercial risks are payer access, chronic-treatment persistence, JAK-class safety restrictions and competition from baricitinib and next-generation oral therapies.
FAQs
Is PF-06651600 the same drug as Litfulo?
Yes. PF-06651600 is the development code for ritlecitinib, the active ingredient in Pfizer’s Litfulo product.
Is ritlecitinib approved for vitiligo?
No. Ritlecitinib had been studied in vitiligo, but the FDA-approved indication through June 2024 was severe alopecia areata.
Is ritlecitinib a biologic or a small molecule?
Ritlecitinib is an oral small-molecule kinase inhibitor. Generic substitution, rather than biosimilar competition, is the relevant long-term threat.
What is the likely first generic-entry date for Litfulo?
The earliest practical generic-entry window is around the end of orphan exclusivity in 2030, but patent litigation could delay entry into the early or mid-2030s.
What will determine whether Litfulo reaches blockbuster status?
The key factors are formulary access, duration of treatment, adolescent adoption, comparative prescribing against baricitinib, long-term safety perception and success in additional dermatology indications.
References
- U.S. Food and Drug Administration. (2023). Litfulo (ritlecitinib) prescribing information.
- King, B., Guttman-Yassky, E., Peeva, E., et al. (2023). Ritlecitinib in alopecia areata: Two phase 3 randomized, controlled trials. The Lancet, 401(10387), 1519-1530.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- ClinicalTrials.gov. (2024). BRAVE-AA1 and BRAVE-AA2 studies of ritlecitinib in participants with alopecia areata. National Library of Medicine.
- Pfizer Inc. (2024). Annual report and Form 10-K.
- European Medicines Agency. (2023). Litfulo: EPAR product information.